Epstein-Barr virus vaccine by 2032?
RegolamentazioneOne-OffSalute e medicinaCinaEuropaCriminalità e giustizia5a
Manifold MarketsSenza KYCDati di risoluzione verificatiDiscretamente calibratoPrevisione della comunità attualeNo 53.5%
Previsori
4
Tipo di domanda
binary
Metodologia
Play-money forecasting platform
Tipo di fonte
Previsione
Dati di mercato
Aggiornato 5 ore fa
Obsoleto26 ott 25, 19:27 UTC31 dic 31, 23:59 UTC
Trend
Mercati Correlati
Domande correlate per il contesto, non un confronto tra contratti equivalenti.
Is Epstein-Barr virus a causative factor in multiple sclerosis?
Manifold MarketsIs the "Promethean virus" in Large Language Models real?
Manifold MarketsWill a vaccine against the Andes virus (hantavirus) be tested in humans before the end of 2027?
Manifold MarketsWill some scientist genetically engineer a virus that is virulent to anyone who isn't Han Chinese by 2038?
Manifold MarketsJeffrey Epstein confirmed to be alive before 2027?
PolymarketWho will be named in Epstein files released in 2026?
KalshiRegole
Resolution: YES if, by 00:00 UTC on Jan 1, 2032, at least one prophylactic EBV vaccine (an active immunization product) has received regulatory authorization for use to prevent EBV infection or EBV‑associated disease (e.g., infectious mononucleosis, post‑transplant lymphoproliferative disease) from any of the following: FDA (U.S.), EMA (EU), MHRA (U.K.), PMDA (Japan), NMPA (China), Health Canada, TGA (Australia), or if the product appears on the WHO Emergency Use Listing (EUL) or the WHO prequalification (PQ) list for EBV prevention.
- What counts:
- Prophylactic EBV vaccines intended to prevent infection and/or clinical disease (e.g., Moderna’s mRNA‑1189; ferritin‑nanoparticle vaccines; other platforms).
- Approvals may be for specific age/risk groups or limited indications (e.g., prevention of mono in adolescents, or prevention of EBV disease in transplant recipients).
- Any formal regulatory approval/authorization meeting the above criteria counts.
- What doesn’t count:
